Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director · President & CEO | August 21, 2026 | August 25, 2026 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director | January 27, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date August 21, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,619,792 |
Ending reported balance
After 2026-08-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-21 · Sale · Disposed 15,009 · Balance 1,663,357 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 2 · 2026-08-21 · Sale · Disposed 15,976 · Balance 1,647,381 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-21 · Sale · Disposed 8,411 · Balance 1,638,970 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 4 · 2026-08-21 · Sale · Disposed 19,178 · Balance 1,619,792 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 24,364 |
Reported balance
Holding disclosure · report date 2026-08-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 24,364 F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 1,000 |
Reported balance
Holding disclosure · report date 2026-08-21 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,000 F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012.
F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children.
Tempest Therapeutics, Inc.
Report date January 27, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2036-01-26 | Direct | 1,230 |
Reported balance
After 2026-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 1,230 · Balance 1,230 F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 1
1 source rowRow 1 · 2026-04-27 · Disposition to issuer · Disposed 115,857 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3: Each Option was fully vested.
F4: Each Option vested in full in connection with consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2024 Filed May 1, 2024 23:59 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 30,000 | $0.99 | $29,700.00 |
DisclosureSEC source: 0001610717-24-000228 · form4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,340,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 20:20 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 7,500 | $7.06 | $52,923.75 |
DisclosureSEC source: 0001610717-24-000211 · form4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,310,933 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $7.015 to $7.09, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:05 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,518 | $7.31 | $11,096.58 |
DisclosureSEC source: 0001610717-24-000199 · form4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,318,433 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 22:22 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0000950170-24-027339 · ownership.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 22:22 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 15,000 | $2.80 | $42,000.00 |
DisclosureSEC source: 0000950170-24-027339 · ownership.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:58 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 22,917 | $8.75 | $200,438.96 |
DisclosureSEC source: 0001610717-24-000085 · form4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,319,951 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:35 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 605,904 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001628280-24-001682 · wk-form4_1705613694.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 605,904 Underlying: Common Stock · 605,904 shares Expires 2034-01-16 F4 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 16, 2024, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:35 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 475,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-001682 · wk-form4_1705613694.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,342,868 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:19 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 11,368 | $4.36 | $49,589.49 |
DisclosureSEC source: 0001628280-23-039901 · wk-form4_1700691579.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 867,868 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan in August 2023. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:41 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 11,419 | $3.55 | $40,558.00 |
DisclosureSEC source: 0001628280-23-030402 · wk-form4_1692823266.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 876,236 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $3.511 to $3.551843, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:53 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (right to buy) · Derivative | 8,200 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001209191-23-038453 · doc4.xml · derivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock · 8,200 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 30,474 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001209191-23-036437 · doc4.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,474 Underlying: Common Stock · 30,474 shares Expires 2033-06-08 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 8,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036437 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,596 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| May 23, 2023 Filed May 25, 2023 12:55 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 11,357 | $3.65 | $41,489.39 |
DisclosureSEC source: 0001104659-23-064394 · tm2316962-7_4seq1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 887,655 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan in February 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:41 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001209191-23-020401 · doc4.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:41 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 4,408 | $11.33 | $49,942.64 |
DisclosureSEC source: 0001209191-23-020401 · doc4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,012 Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:41 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 15,000 | $3.32 | $49,800.00 |
DisclosureSEC source: 0001209191-23-020401 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 22:39 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 13,449 | $3.00 | $40,360.45 |
DisclosureSEC source: 0001567619-23-003771 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 896,012 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:22 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 1,124,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001567619-23-000639 · doc1.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,000 Underlying: Common Stock · 1,124,000 shares Expires 2033-01-05 F4 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:22 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000639 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,461 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 5,936 | $1.95 | $11,571.04 |
DisclosureSEC source: 0001567619-22-020847 · doc1.xml · nonDerivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,461 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 121 | $1.94 | $234.97 |
DisclosureSEC source: 0001567619-22-020847 · doc1.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,397 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 162 | $1.94 | $314.28 |
DisclosureSEC source: 0001567619-22-020847 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,518 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 23:03 UTC | ARDELYX, INC. ARDX · Entity 4972 | PurchaseCommon Stock | 3,000 | $0.62 | $1,856.40 |
DisclosureSEC source: 0001567619-22-016956 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,680 F1 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2022. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 21:43 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 76 | $0.98 | $74.50 |
DisclosureSEC source: 0001567619-22-016644 · doc1.xml · nonDerivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,680 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 21:43 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 54 | $0.98 | $52.93 |
DisclosureSEC source: 0001567619-22-016644 · doc1.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,756 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 21:43 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 6,016 | $0.98 | $5,917.94 |
DisclosureSEC source: 0001567619-22-016644 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,810 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:09 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001179110-22-003376 · edgar.xml · derivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2032-06-16 F1 · derivative.exercise_date: Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:10 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 45,423 | $0.00 Strike: $8.55 | $0.00 |
DisclosureSEC source: 0001209191-22-035842 · doc4.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,423 Underlying: Common Stock · 45,423 shares Expires 2032-06-09 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:10 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 12,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035842 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,420 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document |
| June 06, 2022 Filed Jun 9, 2022 00:00 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,144 | $0.64 | $1,362.94 |
DisclosureSEC source: 0001567619-22-012552 · doc1.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,826 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| June 06, 2022 Filed Jun 9, 2022 00:00 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 101,480 | $0.65 | $66,053.33 |
DisclosureSEC source: 0001567619-22-012552 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,970 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 20, 2022 Filed May 23, 2022 20:32 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 6,124 | $0.67 | $4,111.65 |
DisclosureSEC source: 0001567619-22-011519 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,450 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan on February 28, 2022. Read SEC document |
| May 02, 2022 Filed May 4, 2022 23:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001209191-22-027241 · doc4.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of the transaction date. Read SEC document |
| May 02, 2022 Filed May 4, 2022 23:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 15,000 | $6.99 | $104,890.50 |
DisclosureSEC source: 0001209191-22-027241 · doc4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,749 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $6.83 to $7.18 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 02, 2022 Filed May 4, 2022 23:30 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 15,000 | $4.79 | $71,850.00 |
DisclosureSEC source: 0001209191-22-027241 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 21:56 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 6,229 | $0.67 | $4,173.43 |
DisclosureSEC source: 0001567619-22-005662 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,574 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 06, 2022 Filed Jan 13, 2022 00:45 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001567619-22-001136 · doc1.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2032-01-06 F4 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 06, 2022 Filed Jan 13, 2022 00:45 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-001136 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,803 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,607 | $0.99 | $2,585.88 |
DisclosureSEC source: 0001567619-21-021162 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 631,803 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| October 08, 2021 Filed Oct 29, 2021 23:58 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-019033 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,410 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,937 shares under the Ardelyx Employee Stock Purchase Plan on February 28, 2021. F3 · balance_after: Reflects the adjusted total which includes the purchase of 2,743 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2021. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 23:56 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 6,635 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0001209191-21-057511 · doc4.xml · derivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 Underlying: Common Stock · 6,635 shares Expires 2031-09-20 F1 · derivative.exercise_date: Vests over three (3) years, with one-third (1/3) of the award vesting on July 1, 2022 and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 22:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,573 | $1.32 | $3,396.36 |
DisclosureSEC source: 0001567619-21-016284 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,730 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 267,892 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001567619-21-014511 · doc1.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 267,892 shares Expires 2021-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | Tax withholdingCommon Stock | 150,343 | $1.64 | $246,562.52 |
DisclosureSEC source: 0001567619-21-014511 · doc1.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,303 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were granted in August 2011 and set to expire on August 11, 2021. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 267,892 | $0.54 | $144,661.68 |
DisclosureSEC source: 0001567619-21-014511 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 01:55 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 4,830 | Not disclosed Strike: $10.25 | Not disclosed |
DisclosureSEC source: 0001140361-21-022785 · form4.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,830 Underlying: Common Stock · 4,830 shares Expires 2031-03-09 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F4 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 01:55 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 9,660 | Not disclosed Strike: $5.90 | Not disclosed |
DisclosureSEC source: 0001140361-21-022785 · form4.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,660 Underlying: Common Stock · 9,660 shares Expires 2030-03-29 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F3 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of February 20, 2020, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 01:55 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 16,784 | Not disclosed Strike: $4.97 | Not disclosed |
DisclosureSEC source: 0001140361-21-022785 · form4.xml · derivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,784 Underlying: Common Stock · 16,784 shares Expires 2028-12-18 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F2 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of January 1, 2019, subject to the reporting person's continued service. These stock options provide for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 23:09 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 36,111 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040384 · doc4.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,111 Underlying: Common Stock · 36,111 shares Expires 2031-06-10 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.